Quanex amends proxy for Tyman deal, discloses updated projections, synergies and lawsuits

Quanex Building Products CORP

Stockholder lawsuits filed in NY state court allege proxy omitted material financial information; company denies merit but amends to avoid delays.
Supplemental disclosures include net debt: Tyman ~$146M, Quanex ~$1M; diluted shares and discount rates for DCF analyses.
Quanex FY2028E revenue $1,371M, Adj. EBITDA $207M; Tyman FY2028E revenue $1,021M, Adj. EBITDA $175M.
Anticipates ~$30M annual run-rate cost synergies from deal, split 30% corporate/listing, 30% procurement, 40% admin/commercial.
UBS fairness opinion adjustments: WACC ranges 12.5%-13.5% for Tyman, 13.0%-14.0% for Quanex; terminal multiples 7.5x-9.5x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.